Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)
-
Upload
heba-abd-allatif -
Category
Health & Medicine
-
view
271 -
download
0
Transcript of Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)
![Page 1: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/1.jpg)
Pediatric Bronchial Asthma Hebatallah M Abdallatif,BCPS
![Page 2: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/2.jpg)
Bronchial Asthma• Asthma is a heterogeneous disease
characterized by chronic airway inflammation.• Asthma is a common and potentially
serious chronic disease that can be controlled.• A chronic inflammatory disorder of the
airways that is caused by a variety of cell types (neutrophils, eosinophils, lymphocytes, mast cells) and cytokines)
![Page 3: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/3.jpg)
Bronchial Asthma
![Page 4: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/4.jpg)
Asthma Pathophysiology
![Page 5: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/5.jpg)
Bronchial Asthma Pathophysiology
Airflow obstruction
Airway hyper-responsiveness
Inflammation
![Page 6: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/6.jpg)
Signs & Symptoms• Wheezing• Cough• Shortness of breath• Chest tightness
![Page 7: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/7.jpg)
Signs & Symptoms (Acute episode)• Breathless during rest• Not interested in feeding• Sit upright• Talk in words (not
sentences)• Usually agitated
![Page 8: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/8.jpg)
Asthma in young children challenges
Wheezing occurs in many young children who do not
have asthma, making diagnosis of asthma difficult.
Lung function tests cannot be performed in this age group to help confirm the diagnosis.
Administering medication to young children may be challenging, and many medications for asthma are
poorly studied in very young children.
Gina 2015 updates
![Page 9: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/9.jpg)
Asthma Predictive Index
• The 2007 National Heart, Lung and Blood Institute (NHLBI) Guidelines for the Diagnosis and Management of Asthma describes the Asthma Predictive Index (API), a guide to determining which small children will likely have asthma in later years
![Page 10: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/10.jpg)
Asthma Predictive Index• High-risk children (under age three)• who have had four or more wheezing episodes in the past year that lasted more than one day that affected sleep, are much more likely to have persistent asthma after the age of five, if they have either of the following
![Page 11: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/11.jpg)
Asthma Predictive Index
![Page 12: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/12.jpg)
Diagnosis• Pulmonary
function test Essential to the
diagnosis and evaluation of asthma
Spirometry is the gold standard for the diagnosis and management of asthma
![Page 13: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/13.jpg)
Diagnosis• Bronchodilator
response (BDR) Postbronchodilator
response criteria of 12% of FEV1 OR 200 ml
![Page 14: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/14.jpg)
Asthma in Egypt• Asthma is the
commonest of all chronic diseases of childhood.• Pediatric asthma
prevalence within Egypt ranged between 7.7% in Nile Delta to 9.4% in Cairo.Egypt J Pediatr Allergy Immunol 2009;7(2):59-64.
![Page 15: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/15.jpg)
Asthma in Egypt• Asthma is a common
cause of emergency room visits and hospital admissions
• Up to one in four children with asthma is unable to attend school regularly because of poor asthma control
Egypt J Pediatr Allergy Immunol 2009;7(2):59-64.
![Page 16: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/16.jpg)
Barriers to Manage Asthma in Egypt
• lack of information• under-use of self management• Over-reliance on acute care• Cultural attitudes towards drugs and drug delivery systems
like for• example steroids and inhalers
Patient Barriers
![Page 17: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/17.jpg)
Treatment GoalsControl asthma by reducing impairment through prevention of chronic and troublesome symptoms (eg, coughing or breathlessness in the daytime, in the night, or after exertion.Reduce the need for a short-acting beta2-agonist (SABA) for quick relief of symptoms (not including prevention of exercise-induced bronchospasm).
Maintain normal activity levels (including exercise and other physical activity and attendance at work or school).
![Page 18: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/18.jpg)
How to treat Asthma
• Assessment and monitoring because asthma varies over time, follow-up every 2-6 weeks is initially necessary• Education: Self-
management education should focus on teaching patients• Control of
environmental factors and comorbid conditions• Pharmacologic
treatment
Guidelines from the National Asthma Education and Prevention Program emphasize the following components of asthma care
![Page 19: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/19.jpg)
How to treat Asthma
Asthma classification at
diagnosis determines which treatment step is
initiated
![Page 20: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/20.jpg)
Classification of asthma for those 0–4 years of age
![Page 21: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/21.jpg)
Classification of Asthma in Those 5–11 Years of Age
![Page 22: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/22.jpg)
Classification of Asthma in Those 12 Years of Age to Adult
![Page 23: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/23.jpg)
Asthma TreatmentRelief Medications• short-acting
bronchodilators ipratropium
Controller Medications• Control agents include
inhaled corticosteroids, inhaled cromolyn or nedocromil, long-acting bronchodilators, theophylline, leukotriene modifiers.• More recent strategies
such as the use of anti-immunoglobulin E (IgE) antibodies (omalizumab).
![Page 24: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/24.jpg)
Reliever Medications
They are used for quick relief of asthma symptoms, such as wheezing, "feeling tight" when breathing, coughing and shortness of breath.
Short-acting beta agonists act within minutes to temporarily relieve these symptoms. They do this by relaxing the tightening (bronchospasm) of the muscle bands around the airways, and are very effective in opening the airways
They do not relieve the swelling or inflammation of the breathing tubes that occurs in individuals with asthma. If you need to use these short-acting beta agonists often, it means that the inflammation is not being controlled.
![Page 25: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/25.jpg)
Reliever Medications
Quick relief medicines come in Metered dose inhalers and in a solution for nebulizers. An oral solution is also available, but is less effective and has more side effects.
Short-acting beta agonists have few severe side effects when used in the recommended dose.
The possible side effects of short-acting inhaled beta agonists include a fast heartbeat, nervousness and shakiness, which usually pass quickly when the medicine is inhaled
![Page 26: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/26.jpg)
Controller Medications
Controller medications work over a period of time to reduce airway inflammation and help prevent asthma symptoms from occurring.Prevent asthma symptoms from occurring and reduce and/or prevent,Inflammation and scarring inside the airways
Do not show immediate results, but work slowly over time• Should be taken daily, even when you are not having symptoms.
![Page 27: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/27.jpg)
Controller Medications
Long-term controller medications may act by providing long-acting bronchodilation .These medications are used together with anti-inflammatory medications for better control of chronic asthma.
Leukotriene modifiers: Leukotriene modifiers, such as zafirlukast and montelukast (Singulair®), affect only one portion of the inflammatory process .
Methylxanthines are theophyllines often used in conjunction with anti-inflammatory medications to provide continuous relief from asthmatic symptoms.
![Page 28: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/28.jpg)
Medications(SABAs)
Mechanism Adverse effects Dosage formsBinds to β2-receptors on airway smooth muscle
i. Agitationii. Irritabilityiii. Tachycardiaiv. Tremorv. Hypokalemiavi. Hyperglycemia
Salbutamol •Nebulization solution (1.25 mg/3 mL; 2.5 mg/3 mL; 5 mg/1 mL)• Metered dose inhaler (MDI) 90 mcg/puff
![Page 29: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/29.jpg)
Medications(Inhaled corticosteroids (ICS)
Mechanism of action
Adverse effects Drugs and dosage forms
Anti-inflammatory activity
Linear growth velocity was reduced by around 1 cm in the first year of treatment for low- to medium-dose ICS; however, the patients caught up later.ii. Adverse effects are generally low because systemic absorption is low.Thrush
Budesonide – Typically dosed twice daily(a)Nebulizer
solution (0.25 mg/2 mL; 0.5 mg/2 mL; 1 mg/2 mL)
Fluticasone – Doses divided twice daily(b)MDI: 44
mcg/puff, 110 mcg/puff, 220 mcg/puff
DPI: 50 mcg/inhalation, 100 mcg/inhalation, 250 mcg/inhalation
![Page 30: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/30.jpg)
ICS plus a long-acting β-agonist (LABA)
Drugs and dosage formsFluticasone/salmeterol (Advair)(a) MDI (dosing 2 puffs twice daily): 45/21 mcg, 115/21 mcg/puff, 230/21 mcg/puff(b) DPI (dosing 1 puff twice daily): 100/50 mcg/inhalation, 250/50 mcg/inhalation, 500/50 mcg/inhalation Budesonide/formoterol (Symbicort): MDI (dosing 2 puffs twice daily): 80/4.5 mcg/puff, 160/4.5 mcg/puffiii. Mometasone/formoterol (Dulera): MDI (dosing 2 puffs twice daily): 100/5 mcg/puff, 200/5 mcg/puff
![Page 31: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/31.jpg)
ICS Doses
![Page 32: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/32.jpg)
Leukotriene antagonists
Mechanism of action
Adverse effects Drugs
Block leukotrienes, which are part of the inflammatory pathway
Usually well tolerated Sedation
Montelukast(a) 6 months – 5 years: 4 mg orally daily(b) 6–14 years: 5 mg orally daily(c) 15 years and older: 10 mg orally dailyii. Zafirlukast(a) 5–11 years: 10 mg orally twice daily(b) 12 years and older: 20 mg orally twice daily
![Page 33: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/33.jpg)
Asthma Treatment
A stepwise approach to pharmacologic therapy
is recommended to gain and maintain control of asthma.
The type, amount, and scheduling of medication is dictated by asthma severity (for initiating therapy) and the level of asthma control (for adjusting
therapy).
![Page 34: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/34.jpg)
Asthma Treatment Steps(0-4 age)
![Page 35: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/35.jpg)
Treatment Steps: 5–11 Years of Age
![Page 36: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/36.jpg)
Treatment Steps:12 Years to Adult
![Page 37: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/37.jpg)
Devices Metered Dose Inhaler• MDIs can be used in a patient at any age with the
use of a spacer.• Children aged four years or younger will generally
require a metered dose inhaler (MDI) via a spacer with a mask
• Children should progress to using a spacer and mouthpiece without mask as soon as they are able.
Dry Powder Inhaler DPIChildren aged over seven years may prefer a dry powder inhaler, such as a Turbuhaler or Accuhaler, as they are less conspicuous than a MDI with a spacer, which may increase compliance.
![Page 38: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/38.jpg)
Spacers• Spacers are
devices that help you get the best from your medicine if you use a metered dose inhaler (MDI).
![Page 39: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/39.jpg)
Spacers with facemask• Can be used with
babies or with younger children who find it hard to use an ordinary spacer with a mouthpiece.
![Page 40: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/40.jpg)
Nebulizers
used to deliver inhaled medications to infants and young children who are unable to use a metered dose inhaler (MDI) and/or to children with severe, symptomatic asthma.
![Page 41: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/41.jpg)
MDI vs NebulizersDouble-blind, randomized, placebo-controlled clinical trialIn Pediatric emergency department inchildren aged 2 to 24 months, 85 patients were enrolled in the nebulizer group and 83 in the spacer group.
Data suggest that metered-dose inhalers with spacers may be as efficacious as nebulizers for the emergency department treatment of wheezing in children aged 2 years or younger.
Delgado A1, Chou KJ, Silver EJ, Crain EF, Arch Pediatr Adolesc Med.
2003 Jan;157(1):76-80
![Page 42: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/42.jpg)
Assessment & Monitoring
Follow-up every 2-6 weeks is initially necessary (when gaining control of the disease) and then every 1-6 months thereafter.
spirometry should be measured every 1-2 years, or more frequently for uncontrolled asthma.
![Page 43: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/43.jpg)
Assessment & Monitoring (0-4 of Age)
![Page 44: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/44.jpg)
Assessment & Monitoring (5-11 of Age)
![Page 45: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/45.jpg)
Asthma Control Test
![Page 46: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/46.jpg)
Reviewing response and adjusting treatment
How often should
asthma be reviewed?
•1-3 months after treatment started, then every 3-12 months•After an exacerbation, within 1 week
![Page 47: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/47.jpg)
Reviewing response and adjusting treatment
Stepping up asthma
treatment
•Sustained step-up, for at least 2-3 months if asthma poorly controlled•Important: first check for common causes (symptoms not due to asthma, incorrect inhaler technique, poor adherence)
![Page 48: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/48.jpg)
Reviewing response and adjusting treatment
Stepping up asthma
treatment
•Short-term step-up, for 1-2 weeks, e.g. with viral infection or allergen•May be initiated by patient with written asthma action plan
•Day-to-day adjustment•For patients prescribed low-dose ICS/formoterol maintenance and reliever regimen*
![Page 49: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/49.jpg)
Reviewing response and adjusting treatment
Stepping down asthma
treatment
•Consider step-down after good control maintained for 3 months•Find each patient’s minimum effective dose, that controls both symptoms and exacerbations
![Page 50: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/50.jpg)
Prepare for step-down
Aim •To find the lowest dose that controls symptoms and exacerbations, and minimizes the risk of side-effects
When •When symptoms have been well controlled and lung function stable for ≥3 months
Prepare •Record the level of symptom control and consider risk factors•Make sure the patient has a written asthma action plan•Book a follow-up visit in 1-3 months•Stepping down ICS doses by 25–50% at 3 month intervals is feasible and safe for most patients
![Page 51: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/51.jpg)
EducationPatient education continues to be
important in all areas of medicine and is
particularly important in asthma
Self-management education should focus on teaching
patients the importance of recognizing their own their level of control and signs of
progressively worsening asthma symptoms
![Page 52: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/52.jpg)
Education Strategies
Environmental control avoidance
strategies Medication use and adherence
Providing written asthma action
plans in partnership with
the patient
![Page 53: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/53.jpg)
Patient Education
cdc.gov
![Page 54: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/54.jpg)
![Page 55: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/55.jpg)
Asthma triggers • An asthma trigger is a thing, activity or
condition that makes asthma worse. • When you encounter a trigger it can
cause a sudden worsening of symptoms, often called an asthma attack, episode or flare-up.
![Page 56: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/56.jpg)
Asthma triggers
![Page 57: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/57.jpg)
Avoidance triggers educational tool
![Page 58: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/58.jpg)
Correct inhaler techniques and use of other devices)
![Page 59: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/59.jpg)
Medication Use in Children
Inhaler technique should be assessed at appointments to ensure adequate
delivery.
![Page 60: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/60.jpg)
Asthma Devices Checklist
![Page 61: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/61.jpg)
Asthma Action Plan•A written care plan for asthma treatment personalized for the patient.
•Asthma triggers should be documented so that the patient can try to avoid them.
•It is important to share the asthma action plan with the school or day care.
![Page 62: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/62.jpg)
Asthma Action Plan model
![Page 63: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/63.jpg)
Asthma Action Plan
![Page 64: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/64.jpg)
Status asthmaticus
an acute asthma exacerbation in which bronchial obstruction is severe and
continues to worsen or not improve
despite the institution of a
adequate standard therapy
![Page 65: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/65.jpg)
PATHOPHYSIOLOGY
Inflammation and edema of bronchial
mucosa,increased mucusproduction with
airway plugging, and bronchospam.
Increased airway resistance, leading to
increase work of breathing, inspiration
starts before termination of the previous expiration
air trapping and hyperinflation.,H
ypoxemia
![Page 66: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/66.jpg)
![Page 67: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/67.jpg)
![Page 68: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/68.jpg)
Dexamethasone vs Predisnolone
A meta-analysis concluded that, in comparing a one- or two-dose dexamethasone regimen with a 5-day prednisolone regimen
There was no difference in relapse rate but patient vomiting was less in those with asthma exacerbations discharged from the ED.
Dexamethasone 0.6 mg/kg/dose (max dose 18 mg) every 24 hours times one or two doses is an option for status asthmaticus treatment in the ED.
Grant E. Keeney, Matthew P. Gray, Andrea K. Morrison, Michael N. Levas, Elizabeth A. Kessler, Garick D. Hill, Marc H. Gorelick, Jeffrey L. Jackson, PediatricsFebruary 2014
![Page 69: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/69.jpg)
Follow-up after an exacerbation
•Follow up all patients regularly after an exacerbation, until symptoms and lung function return to normal•Patients are at increased risk during recovery from an exacerbation.
•Exacerbations often represent failures in chronic asthma care and they provide opportunities to review the patient’s asthma management.
![Page 70: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/70.jpg)
![Page 71: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/71.jpg)
At follow-up visits (Check)
The patient’s understanding of the cause of the flare-up
Adherence with medications, and understanding of their
purpose
Inhaler technique skills
Written asthma action plan
![Page 72: Bronchial asthma clinical pharmacist hebatallah m abdallatif,bcps (1)](https://reader036.fdocuments.us/reader036/viewer/2022062412/5878dc251a28ab917a8b7345/html5/thumbnails/72.jpg)